Skip to main content

$0.160 -0.005 (-3.03%)

High

$0.16

Low

$0.16

Trades

13

Turnover

$11,013

Volume

68,980
30 June 2023 at 12:18pm
Register to track KZA and receive email alerts.

Kazia launches new paxalisib phase II clinical trial

StockBot

416,823 posts

KZA released this announcement to the ASX on 15 June 2021, 9:08. The announcement is marked as price sensitive, and is 5 page(s) in length and 240.18kb in size.

You can view all announcements from KZA and see how they appear on a price chart on the announcements page.

At the date of this announcement, KZA was 0.001% short sold according to ASIC data. It was ranked the 655th most shorted stock on the ASX. It remains ranked 657th as of the latest reported data (01 November 2023).

Other Recent Announcements from KZA
Kazia Corporate Update and Corporate Presentation 26 June 2023, 9:17
Launch of LUMOS2 Study 8 June 2023, 8:23
Constitution 7 June 2023, 14:05
Kazia launches new paxalisib phase II clinical trial 15 June 2021, 9:08
Kazia paxilisib in Dana Farber study enrols first patient 7 June 2021, 9:40
Appendix 3Y for 3 directors 2 June 2021, 14:59
Change in substantial holding 27 May 2021, 8:25
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track KZA and receive email alerts.